These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11966745)

  • 1. Reduced capillary permeability and capillary density in the skin of GH-deficient adults: improvement after 12 months GH replacement.
    Oomen PH; Beentjes JA; Bosma E; Smit AJ; Reitsma WD; Dullaart RP
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):519-24. PubMed ID: 11966745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle.
    Hettema ME; Zhang D; Stienstra Y; Oomen PN; Smit AJ; Kallenberg CG; Bootsma H
    Rheumatology (Oxford); 2008 Sep; 47(9):1409-12. PubMed ID: 18628286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
    Span JP; Pieters GF; Sweep CG; Hermus AR; Smals AG
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study.
    Juul A; Andersson AM; Pedersen SA; Jørgensen JO; Christiansen JS; Groome NP; Skakkebaek NE
    Horm Res; 1998; 49(6):269-78. PubMed ID: 9623518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
    Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study.
    Christ ER; Cummings MH; Lumb PJ; Crook MA; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):173-9. PubMed ID: 10468987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
    Toogood AA; Shalet SM
    J Clin Endocrinol Metab; 1999 Jan; 84(1):131-6. PubMed ID: 9920073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone binding protein correlates strongly with leptin and percentage body fat in GH-deficient adults, is increased by GH replacement but does not predict IGF-I response.
    Florkowski CM; Barnard R; Livesey JH; Veveris T; Espiner EA; Donald RA
    Growth Horm IGF Res; 1999 Feb; 9(1):35-40. PubMed ID: 10207506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensin-aldosterone system.
    Ekman B; Ohman PK; Arnqvist HJ; Lindström T; Nyström FH
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):473-9. PubMed ID: 12354129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism.
    Isidori AM; Kaltsas GA; Perry L; Burrin JM; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2003 May; 58(5):601-11. PubMed ID: 12699442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults.
    Gilchrist FJ; Murray RD; Shalet SM
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):363-70. PubMed ID: 12201829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement.
    Colao A; Di Somma C; Rota F; Di Maio S; Salerno M; Klain A; Spiezia S; Lombardi G
    J Clin Endocrinol Metab; 2005 May; 90(5):2659-65. PubMed ID: 15713715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual igf-I responsiveness to a fixed regimen of low-dose growth hormone replacement is increased with less variability in obese compared to non-obese adults with severe growth hormone deficiency.
    Yuen KC; Cook DM; Rumbaugh EE; Cook MB; Dunger DB
    Horm Res; 2006; 65(1):6-13. PubMed ID: 16340214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.